- Home
- BZH vs AUPH Comparison
BZH vs AUPH Comparison
Compare BZH & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZH
- AUPH
- Stock Information
- Founded
- BZH 1985
- AUPH 1993
- Country
- BZH United States
- AUPH Canada
- Employees
- BZH N/A
- AUPH N/A
- Industry
- BZH Homebuilding
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- BZH Consumer Discretionary
- AUPH Health Care
- Exchange
- BZH Nasdaq
- AUPH Nasdaq
- Market Cap
- BZH 666.1M
- AUPH 1.1B
- IPO Year
- BZH 1994
- AUPH 1999
- Fundamental
- Price
- BZH $23.58
- AUPH $7.59
- Analyst Decision
- BZH Strong Buy
- AUPH Strong Buy
- Analyst Count
- BZH 3
- AUPH 2
- Target Price
- BZH $33.00
- AUPH $11.50
- AVG Volume (30 Days)
- BZH 335.9K
- AUPH 1.6M
- Earning Date
- BZH 07-31-2025
- AUPH 07-31-2025
- Dividend Yield
- BZH N/A
- AUPH N/A
- EPS Growth
- BZH N/A
- AUPH N/A
- EPS
- BZH 3.10
- AUPH 0.27
- Revenue
- BZH $2,436,131,000.00
- AUPH $247,295,000.00
- Revenue This Year
- BZH N/A
- AUPH $12.15
- Revenue Next Year
- BZH $14.27
- AUPH $18.31
- P/E Ratio
- BZH $7.70
- AUPH $28.53
- Revenue Growth
- BZH 13.50
- AUPH 29.20
- 52 Week Low
- BZH $17.37
- AUPH $5.20
- 52 Week High
- BZH $38.22
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- BZH 63.10
- AUPH 40.36
- Support Level
- BZH $21.88
- AUPH $7.29
- Resistance Level
- BZH $24.30
- AUPH $8.86
- Average True Range (ATR)
- BZH 0.83
- AUPH 0.34
- MACD
- BZH 0.17
- AUPH -0.06
- Stochastic Oscillator
- BZH 79.87
- AUPH 19.37
About BZH Beazer Homes USA Inc.
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in over 13 states and over 22 metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the leading sources of revenue for the company. Key metro areas include Atlanta, Las Vegas, Los Angeles, Orlando, and Tampa. The company also focuses on land purchasing and development to support future construction efforts as well as mortgage services for its homebuyers.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.